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Edited by Shou-Wei DingAbstract This study describes a strategy to develop LNA-mod-
iﬁed small interfering RNA (siRNAs) against the highly struc-
tured 5 0 UTR of coxsackievirus B3 (CVB-3), which is an
attractive target site due to its high degree of conservation.
Accessible sites were identiﬁed based on structural models and
RNase H assays with DNA oligonucleotides. Subsequently,
LNA gapmers, siRNAs, siLNAs and small internally segmented
interfering RNA (sisiLNAs) were designed against sites, which
were found to be accessible in the in vitro assays, and tested in
reporter assays and experiments with the infectious virus. The
best siLNA improved viability of infected cells by 92% and ex-
erted good antiviral activity in plaque reduction assays.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Coxsackievirus B3 (CVB-3) is a member of the picornavirus
family, which contains a single stranded RNA genome in plus-
strand orientation [1,2]. The 5 0 UTR of CVB-3 plays an impor-
tant role in key steps of the viral life cycle, replication and
translation. To initiate the latter process, it contains an Inter-
nal Ribosome Entry Site (IRES), which allows protein synthe-
sis in a cap-independent manner. CVB-3 can cause viral heart
muscle infections, against which no speciﬁc drugs exist to date.
In the last years RNA interference (RNAi) has emerged as a
technique that might develop into a new class of therapeutics
[3]. It has particularly been used as a novel antiviral approach
and the ﬁrst clinical trials to use small interfering RNAs
(siRNAs) or vector-expressed short hairpin RNAs have already
been initiated [4]. Consequently, a number of groups have used
RNAi-based approaches against CVB-3 [5–10]. Since the emer-Abbreviations: CVB-3, coxsackievirus B3; IRES, internal ribosome
entry site; RNAi, RNA interference; siRNA, small interfering RNA;
sisiRNA, small internally segmented interfering RNA
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viral applications, the 5 0 UTR of CVB-3 is a preferable target
region for siRNAs: It is highly conserved and therefore unlikely
to tolerate mutations and it is functional by structural features.
While protein-coding regions will tolerate mutations in wobble
positions, substitutions in the IRES will lead to structural alter-
ations, thereby compromising its function. A previous study
demonstrated that siRNAs against the conserved cis-acting rep-
lication element within the enterovirus coding region drastically
reduces the risk to enrich escape mutants [11]. Interestingly,
however, a number of siRNAs against the 5 0 UTR of CVB-3
have been tested, but none of them exerted signiﬁcant antiviral
activity [8,9,12,13]. Since it is well known that targetRNA struc-
tures can greatlymodulate the eﬃciency of antisense oligonucle-
otides and ribozymes [14] it is conceivable that the failure to
target the viral UTR by siRNAs is due to the tight structure of
the IRES element. While several reports stress the importance
of the thermodynamic features of the siRNA for its activity
[15,16], others have shown that the structure of the target
RNA might be detrimental for the silencing as well [17–19].
Locked nucleic acid (LNA) is a widely used modiﬁcation to
improve the properties of oligonucleotides like aptamers [20]
and antisense oligonucleotides [21] due to its high target aﬃn-
ity and nuclease resistance. The incorporation of LNA is toler-
ated in various positions of the siRNA and can even improve
its eﬃciency [22,23]. A three-stranded construct with two short
strands complementary to the antisense strand dubbed small
internally segmented interfering siRNAs (sisiRNAs) was re-
cently shown to posses improved silencing properties [24]. Fur-
thermore, LNA-modiﬁed siRNAs were successfully used for
functional investigations of the silencing mechanism [25] and
for in vivo applications [26].
Here, we describe a strategy to obtain active siLNAs target-
ing the tightly structured 5 0 UTR of CVB-3. The approach
comprises RNase H experiments, reporter assays in cell culture
as well as virus assays and led to the identiﬁcation of active
molecules for the inhibition of virus replication.2. Materials and methods
2.1. Oligonucleotides
DNA oligonucleotides and siRNAs were purchased from Purimex
(Go¨ttingen, Germany). LNA gapmers and LNA-modiﬁed siRNAsblished by Elsevier B.V. All rights reserved.
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of all oligonucleotides are summarized in Supplementary Tables 1
and 2.
2.2. RNase H assay
The 5 0 UTR of CVB-3 (nucleotides 1–742, GenBank accession No.
M33854) was cloned into pcDNA 3.1/CT-GFP (Invitrogen, Karlsruhe,
Germany). After linearization of the plasmid, the 5 0 UTR was tran-Fig. 1. Identiﬁcation of accessible sites of the 5 0 UTR of CVB-3. (A) Represen
RNase H. Lanes 1–22 represent RNA cleavage induced by 19mer DNA olig
without DNA oligonucleotide. The diagram shows the extent of target RNA
given for each oligonucleotide. (B) Secondary structure model of the 5 0 UTR
oligonucleotides according to the screening shown in (A) are indicated.scribed in vitro using the Ribomax Kit (Promega, Madison, WI).
RNase H assays were carried out as described previously [27] with
an additional RNA renaturation step before starting the reaction.
2.3. Cell culture reporter assays
For reporter assays, a fusion construct of GFP and the viral 5 0 UTR
was used as described in [12]. Cos-7 cells were cotransfected with this
plasmid and the respective oligonucleotide using Lipofectamine 2000tative agarose gel showing degradation of in vitro transcribed RNA by
onucleotides against speciﬁc sites of the 5 0 UTR. (C) Control reaction
degradation. Average and S.D. of three independent experiments are
of CVB-3 according to Bailey et al. [29]. Target sites of most eﬃcient
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and a Western blot with rabbit GFP antiserum (Invitrogen) was car-
ried out. The procedure is described in detail in [28] except that the
ECL Kit (Pierce, Rockford, IL) was used for chemoluminescence.
2.4. Plaque reduction and cell viability assay
Plaque reduction and cell viability assays were performed as described
before [12]. Brieﬂy, HeLa cells were transfected with the respective LNA
gapmer, siRNAs or LNA-modiﬁed siRNA and subsequently infected
with CVB-3 (Nancy, ATCC No. VR-30). For plaque reduction assays,
cells were overlaid with agar containing Eagles MEM. Cells were
stainedwith neutral red and the plaque number was counted after 3 days
of incubation at 37 C. Cell viability was determined with the Cell Pro-
liferation Kit II 48 h post-inoculation (Roche, Mannheim, Germany).3. Results and discussion
3.1. Identiﬁcation of accessible target sites
For the development of an eﬃcient siRNA against the
5 0 UTR of CVB-3 we ﬁrst aimed at identifying accessible targetFig. 2. Western blots showing downregulation of GFP reporter by LNA gap
and 20 (at 100 nM concentration). (B) siRNAs Nos. 18 and 20 as well as LNA
4-4 was used at 20 nM concentration to minimize toxicity. Controls (ctr) are
Actin is shown as a loading control.
Fig. 3. Viability of HeLa cells 48 h after inoculation with CVB-3. Cells wer
Mock-cells were neither transfected nor inoculated, mock + lipo-cells were t
oligonucleotide; virus and virus + lipo: cells inoculated with the virus in the p
independent experiments are given.sites. Based on a recently published secondary structure model
[29], we designed a set of 22 DNA antisense molecules being 19
nucleotides in length (Supplementary Table 1). Since these
DNA oligonucleotides were supposed to help identifying suit-
able target sites for siRNAs, well-known thermodynamic fea-
tures of siRNAs (relative stability of the ends, preference for
bases in certain positions according to Reynolds et al. [30])
against these target sites were taken into consideration and se-
quences that would result in highly structured antisense
strands of the siRNA were excluded, since this feature was also
found to be detrimental to silencing [31]. Furthermore, regions
which are prone to point mutations were omitted.
In order to assess accessibility of the target RNA for hybrid-
ization to complementary oligonucleotides, cleavage of an in
vitro transcript of the 5 0 UTR mediated by RNase H in the
presence of either of the 22 DNA oligonucleotides was deter-
mined (Fig. 1A). Interestingly, only seven oligonucleotides
were capable of inducing more than 50% target RNA cleavage
and only two of them led to more than 90% degradation. Themers, siRNAs and modiﬁed variants thereof. (A) siRNAs Nos. 4, 6, 18
modiﬁed variants siLNA and sisiRNA at 100 nM concentration. LNA
shown for each type of oligonucleotide at the respective concentration.
e pre-treated with increasing concentrations of the LNA gapmer 4-4.
reated with the transfection reagent only. LNA ctr: unrelated control
resence or absence of the transfection agent. Average and S.D. of four
3064 M. Dutkiewicz et al. / FEBS Letters 582 (2008) 3061–3066location of the four sites with highest accessibility to comple-
mentary 19mer oligonucleotides is depicted in the schematic
secondary structure model in Fig. 1B.
3.2. Reporter assays
Four siRNAs and three LNA gapmers against the most
accessible sites 4, 6, 18 and 20 (Supplementary Table 2) were
tested in further assays. For the LNA gapmers a design with
three LNA monomers at each end and a total length of 16
nucleotides was chosen. Since each 19mer sequence contains
four 16mer sequences, further RNase H assays with 16mer
DNAs were performed to identify the best target site for the
LNA gapmer (data not shown). For the chosen LNA gapmers
4-4, 6-3 and 18-2 the ﬁrst number reﬂects the target site, while
the second indicates the ﬁrst position of the 16mer within the
19mer sequence.
As a ﬁrst qualitative test of the activity of various siRNAs
and LNAs, GFP-reporter assays were carried out. To this
end, the viral 5 0 UTR was cloned downstream of GFP and
co-transfection assays with the reporter plasmid and theFig. 4. Protective eﬀect of siRNAs and LNA modiﬁed variants thereof. (A)
transfected with 100 nM siRNA, siLNA and sisiLNA as indicated prior to in
siLNA_20, sisiLNA_20 and the respective controls. The titre of CVB-3 is
oligonucleotides relative to virus-only treated cells. All data are means and S.D
(A) or in duplicate (B).respective siRNA were performed. As can be seen in Fig.
2A, siRNAs Nos. 18 and 20 were found to be superior as com-
pared to Nos. 4 and 6. This is somewhat surprising with regard
to the results of the RNase H assay. It should be mentioned
that a large scale comparison of siRNAs and antisense oligo-
nucleotides binding the same position on the target mRNA re-
vealed a good correlation of their activity, but some exceptions
were noted [32]. A possible explanation was given recently,
when Westerhout and Berkhout elegantly demonstrated that
an accessible target 3 0 end to be most important for RNAi-
mediated inhibition [17], thus showing that siRNAs and anti-
sense oligonucleotides not necessarily follow the same design
rules in all cases.
To further improve the eﬃciency of the siRNAs, LNA
monomers were incorporated into the sense strand and the 3 0
end of the antisense strand. Furthermore, sisiLNAs with a seg-
mented sense strand were synthesised (Supplementary Table
2). The modiﬁcations have previously been shown to enhance
nuclease resistance, to increase eﬃciency by improving RISC
loading and to reduce oﬀ-target eﬀects [23,24]. Fig. 2B showsViability of HeLa cells 48 h after inoculation with CVB-3. Cells were
oculation. (B) Plaque reduction assay of cells treated with siRNA_20,
expressed as plaque-forming units (p.f.u.)/ml of cells pre-treated with
. from four independent experiments each performed in quadruplicate
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mer 4-4 were capable of inhibiting expression of the fusion
construct almost to completion.
3.3. Virus assays
The crucial test for the siRNAs and LNAs was, of course,
their antiviral activity. We therefore performed cell viability
assays in HeLa cells infected with CVB-3 (Nancy strain).
The LNA gapmer 4-4 exhibited partial inhibitory activity
increasing cell viability to approximately 55% (Fig. 3). A pla-
teau for the inhibitory activity way reached at 50 nM and at
very high concentrations (500 nM) cell viability was even re-
duced most likely due to toxic eﬀects of the oligonucleotide (re-
sults not shown).
Interestingly, siRNA_18 and LNA-derivatives thereof did
not have any antiviral eﬀect despite being very eﬃcient in the
reporter assay (Fig. 4A). The lack of activity can be explained
either by the formation of diﬀerent local structures in the GFP-
fusion construct and the infectious virus or by binding of pro-
teins to the viral RNA. This ﬁnding clearly demonstrates that
results from reporter assays cannot always be transferred to
the native situation.
More important, however, was the ﬁnding, that siRNA No.
20 exerted good antiviral activity. In cell viability assays, the
siLNA protected cells against lysis by the virus by more than
90% (Fig. 4A). The protective eﬀect of the siRNA and sisiLNA
was approximately 80% and 50%, respectively. The superiority
of the siLNA in comparison to the siRNA and sisiLNA
against the best target site identiﬁed for the 5 0 UTR of
CVB-3 was conﬁrmed in plaque reduction assays, which dem-
onstrated successful reduction of the virus titer (Fig. 4B). In
addition to the shown reduction of the plaque number, the
plaque morphology was characterized by a smaller diameter
in comparison to virus controls in the absence of siRNAs.
The small plaque morphology also represents reduced virus
reproduction.
While genome-wide RNAi-libraries exist for several mam-
malian organisms that allow silencing of any chosen endoge-
nously expressed gene, the development of siRNAs with
good antiviral potency still remains challenging. This is
particularly true for highly structured target regions like the
5 0 UTR of picornaviruses. We describe in our present study
a stepwise approach to inhibit replication of CVB-3. This strat-
egy comprises computer-based and experimentally validated
secondary structure models, in vitro RNase H assays,
GFP-reporter assays and the use of LNA-modiﬁed siRNAs.
We ﬁnally succeeded in eﬃciently inhibiting CVB-3. To the
best of our knowledge this is the ﬁrst report on an eﬃcient
siRNA against the highly conserved 5 0 UTR of CBV-3 which
is an attractive target region for siRNAs since it is unlikely to
easily accumulate mutations that allow viral escape.
The strategy described here might not only help to design
siRNAs against any highly structured virus RNA but might
also oﬀer help for diﬃcult to silence endogenously expressed
genes. Kruger et al. recently published their experience with
large-scale siRNA screening [33]. While 70% of the targets
could easily be silenced with siRNAs and the expression of fur-
ther genes was successfully inhibited after testing a larger num-
ber of siRNAs, 6% of the targets turned out to be refractory to
silencing even with up to 10 diﬀerent, well-designed siRNAs.
This failure is likely to be due to structural features of the tar-
geted RNAs. We suggest that initial mapping of accessibilitywith a large set of DNA oligonucleotides and improvement
of the siRNA by introducing LNA monomers might help to
overcome these problems. More comprehensive studies, how-
ever, will be necessary to conﬁrm, whether this approach is
generally applicable.
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